SCHEMBL20046681

SCHEMBL20046681

O=C(O)c1ccc(CCCCCCO)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HA1 P13674 2/20 0.47
P4HTM Q9NXG6 2/20 0.47
MIF P14174 1/20 0.46
GABRP O00591 1/20 0.44
GABRD O14764 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRB1 P18505 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRA2 P47869 1/20 0.44
GABRB2 P47870 1/20 0.44
GABRA4 P48169 1/20 0.44
GABRE P78334 1/20 0.44
GABRA6 Q16445 1/20 0.44
GABRG1 Q8N1C3 1/20 0.44
GABRG3 Q99928 1/20 0.44
GABRQ Q9UN88 1/20 0.44
NAPRT Q6XQN6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8229222 1.00 P4HA1 (0.47) P4HA1P4HTMMIFGABRPGABRD
SCHEMBL30432120 1.00 P4HA1 (0.47) P4HA1P4HTMMIFGABRPGABRD
SCHEMBL20423258 0.98 P4HA1 (0.48) P4HA1P4HTMMIFGABRPGABRD
SCHEMBL20046092 0.93 P4HA1 (0.50) P4HA1P4HTMMIFGABRPGABRD
SCHEMBL152571 0.86 P4HA1 (0.53) P4HA1P4HTMMIFGABRPGABRD
SCHEMBL10666643 0.85 RARB (0.58) ALDH1A1HCAR3MAPTRARB
SCHEMBL10661712 0.85 RARB (0.58) ALDH1A1HCAR3MAPTRARB
SCHEMBL10660563 0.85 RARB (0.58) ALDH1A1HCAR3MAPTRARB
SCHEMBL10658847 0.85 RARB (0.58) ALDH1A1HCAR3MAPTRARB
SCHEMBL10663476 0.83 HCAR3 (0.57) ALDH1A1HCAR3MAPTRARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4509184-A2 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas Operations, Inc. (US) 2025-02-19 EP disclosed
US-20250034096-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2025-01-30 US disclosed
EP-3526202-B1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS INC (US) 2025-01-08 EP disclosed
US-12077509-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2024-09-03 US disclosed
US-11964945-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2024-04-23 US disclosed
US-11952347-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2024-04-09 US disclosed
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 US disclosed
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 US disclosed
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 US disclosed
CN-111892577-B Compounds and methods for androgen receptor targeted degradation 阿尔维纳斯运营股份有限公司 2023-07-07 CN disclosed
US-20210009528-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas, Inc. 2021-01-14 US disclosed
US-10844021-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2020-11-24 US disclosed
CN-111892577-A Compounds and methods for targeted degradation of androgen receptor 阿尔维纳斯运营股份有限公司 2020-11-06 CN disclosed
EP-3660004-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas Operations, Inc. (US) 2020-06-03 EP disclosed
US-20200095205-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2020-03-26 US disclosed
US-10584101-B2 Compounds and methods for the targeted degradation of androgen receptor Arvinas, Inc. (US) 2020-03-10 US disclosed
EP-3526202-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas, Inc. (US) 2019-08-21 EP disclosed
WO-2018071606-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas, Inc. (US) 2018-04-19 WO disclosed
US-20180099940-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2018-04-12 US disclosed
US-20180099940-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2018-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN P4HA1 2436/4885P4HTM 1668/4885MIF 3807/4885
US-20210009528-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN P4HA1 2436/4885P4HTM 1668/4885MIF 3807/4885
US-20180099940-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN P4HA1 2468/4885P4HTM 1711/4885MIF 3757/4885
US-10844021-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN P4HA1 2468/4885P4HTM 1711/4885MIF 3757/4885
US-11964945-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN P4HA1 2468/4885P4HTM 1711/4885MIF 3757/4885
US-11952347-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN P4HA1 2436/4885P4HTM 1668/4885MIF 3807/4885
US-12077509-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN P4HA1 2436/4885P4HTM 1668/4885MIF 3807/4885
US-20250034096-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN P4HA1 2436/4885P4HTM 1668/4885MIF 3807/4885
US-20200095205-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN P4HA1 2468/4885P4HTM 1711/4885MIF 3757/4885
US-10584101-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN P4HA1 2468/4885P4HTM 1711/4885MIF 3757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.